Evidence map›Paper›PMID 42445007›Full record

ArticleACS medicinal chemistry letters2026

Identification and Biological Evaluation of Juglone-Derived STAT3 Inhibitors against Colorectal Cancer.

Jiaxing Zhang, Xiangquan Li, Zhejun Zhang, Junyao Wen, Tong Ding, Yaochuan Zhang, Zhao Deng, Yixian Liao, Wenying Yu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS medicinal chemistry letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jiaxing ZhangState Key Laboratory of Natural Medicines, China Pharmaceutical University, No. 639 Longmian Dadao, Nanjing 211198, China.
Xiangquan LiState Key Laboratory of Natural Medicines, China Pharmaceutical University, No. 639 Longmian Dadao, Nanjing 211198, China.
Zhejun ZhangState Key Laboratory of Natural Medicines, China Pharmaceutical University, No. 639 Longmian Dadao, Nanjing 211198, China.
Junyao WenState Key Laboratory of Natural Medicines, China Pharmaceutical University, No. 639 Longmian Dadao, Nanjing 211198, China.
Tong DingSchool of Life Science and Technology, China Pharmaceutical University, No. 639 Longmian Dadao, Nanjing 211198, China.
Yaochuan ZhangState Key Laboratory of Natural Medicines, China Pharmaceutical University, No. 639 Longmian Dadao, Nanjing 211198, China.
Zhao DengSchool of Life Science and Technology, China Pharmaceutical University, No. 639 Longmian Dadao, Nanjing 211198, China.
Yixian LiaoState Key Laboratory of Natural Medicines, China Pharmaceutical University, No. 639 Longmian Dadao, Nanjing 211198, China.ORCID https://orcid.org/0000-0002-7470-9464
Wenying YuState Key Laboratory of Natural Medicines, China Pharmaceutical University, No. 639 Longmian Dadao, Nanjing 211198, China.ORCID https://orcid.org/0000-0003-1567-1723

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aberrant activation of signal transducer and activator of transcription 3 (STAT3) drives colorectal cancer progression by promoting cell proliferation, inhibiting apoptosis, and facilitating angiogenesis, making STAT3 a highly promising therapeutic target. In this study, a series of juglone-based quinone derivatives were designed, synthesized, and systematically evaluated as STAT3 inhibitors. Among them, compound YZZ-24 exhibited the strongest STAT3 binding affinity (

Indexed as

Colorectal cancerNatural productsPhosphorylationSTAT3

Identifiers

PMID42445007
PMCPMC13358963

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.